Bio-Techne (TECH)
NASDAQHealth CareBiotechnologySnapshot 2026-07-08
$70.61-0.44%
Close 2026-07-07 · 1-day change
Reading TECH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TECH free→NASDAQHealth CareBiotechnologySnapshot 2026-07-08
Reading TECH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TECH free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
TECH's growth depends on its ability to expand through partnerships and acquisitions. Recent performance has been strong, with revenue growth showing potential. It trades at 38× P/E, slightly above the 35× peer median. The market seems to expect more growth than what is likely. If TECH cuts guidance on the next call, it could face a significant drop. Peer multiples imply a price about 32% below where it trades; this read is provisional.
Trailing returns as of 2026-07-07. TECH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering TECH (as of Jul 2026).
Based on 8 Wall Street analysts offering 12-month price targets for TECH in the last 4 months.
A consensus fair price across 13 valuation methods, at three horizons. Current price $70.61. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Advances: Achieve revenue growth
Expansion supports revenue growth through innovative product offerings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $70.61
The last 12 months of price, then the range of analyst 12-month targets from today’s $70.61.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Acquisition enhances growth potential and market position.
Advances: Achieve revenue growth
Acquisition enhances growth potential and market position.
Acquisition enhances growth potential and market position.
Acquisition enhances growth potential and market position.
New collaboration enhances growth potential through innovative products.